2020
Nationwide patterns of hemorrhagic stroke among patients hospitalized with brain metastases: influence of primary cancer diagnosis and anticoagulation
Lee V, Jairam V, Yu JB, Park HS. Nationwide patterns of hemorrhagic stroke among patients hospitalized with brain metastases: influence of primary cancer diagnosis and anticoagulation. Scientific Reports 2020, 10: 10084. PMID: 32572113, PMCID: PMC7308286, DOI: 10.1038/s41598-020-67316-8.Peer-Reviewed Original ResearchConceptsBrain metastasesLong-term anticoagulationIntracerebral hemorrhageKidney cancerHigh riskUtilization Project Nationwide Inpatient SampleDiagnosis of ICHHospital-related characteristicsRisks of anticoagulationPrimary cancer diagnosisMultivariable logistic regressionNationwide Inpatient SampleLonger lengthDiagnosis of melanomaMann-Whitney UHemorrhagic strokeNeurologic dysfunctionConcurrent diagnosisSignificant morbiditySecondary diagnosisInpatient SampleBaseline differencesDecreased qualityAnticoagulationHealthcare costsProceedings of the ASTRO-RSNA Oligometastatic Disease Research Workshop
Yu JB, Brock KK, Campbell AM, Chen A, Diaz R, Escorcia F, Gupta G, Hrinivich WT, Joseph S, Korpics M, Onderdonk BE, Pandit-Taskar N, Wood B, Woodward WA. Proceedings of the ASTRO-RSNA Oligometastatic Disease Research Workshop. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: 539-545. PMID: 32434040, DOI: 10.1016/j.ijrobp.2020.05.018.Peer-Reviewed Original ResearchDefining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document
Lievens Y, Guckenberger M, Gomez D, Hoyer M, Iyengar P, Kindts I, Méndez Romero A, Nevens D, Palma D, Park C, Ricardi U, Scorsetti M, Yu J, Woodward W. Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. Radiotherapy And Oncology 2020, 148: 157-166. PMID: 32388150, DOI: 10.1016/j.radonc.2020.04.003.Peer-Reviewed Original ResearchMeSH KeywordsConsensusDiagnostic ImagingHumansNeoplasm MetastasisNeoplasmsRadiation OncologyRetrospective StudiesConceptsMetastasis-directed radiotherapyDefinition of oligometastatic diseaseOligometastatic diseaseMetastatic sitesAbsence of clinical dataMetachronous oligometastatic diseaseRadiation oncology perspectiveDisease-free intervalSingle-centre seriesContext of radiotherapyPatient inclusion criteriaProgression-freeMetastatic locationsCurative intentMetastatic lesionsOverall survivalPrimary tumorSystemic therapyOncological perspectiveQuality-of-lifeClinical dataRadiotherapyLocal controlConsensus documentInclusion criteriaPembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial
Goldberg SB, Schalper KA, Gettinger SN, Mahajan A, Herbst RS, Chiang AC, Lilenbaum R, Wilson FH, Omay SB, Yu JB, Jilaveanu L, Tran T, Pavlik K, Rowen E, Gerrish H, Komlo A, Gupta R, Wyatt H, Ribeiro M, Kluger Y, Zhou G, Wei W, Chiang VL, Kluger HM. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. The Lancet Oncology 2020, 21: 655-663. PMID: 32251621, PMCID: PMC7380514, DOI: 10.1016/s1470-2045(20)30111-x.Peer-Reviewed Original ResearchConceptsBrain metastasis responseYale Cancer CenterPD-L1 expressionPhase 2 trialUntreated brain metastasesBrain metastasesAdrenal insufficiencyAdverse eventsMetastasis responseCNS diseaseCancer CenterCohort 2Cohort 1Eastern Cooperative Oncology Group performance statusTreatment-related serious adverse eventsModified Response Evaluation CriteriaStage IV NSCLCTreatment-related deathsAcute kidney injuryPD-1 blockadeSerious adverse eventsSolid Tumors criteriaPhase 2 studyProportion of patientsResponse Evaluation Criteria
2017
Discrepancies between biomarkers of primary breast cancer and subsequent brain metastases: an international multicenter study
Kaidar-Person O, Meattini I, Jain P, Bult P, Simone N, Kindts I, Steffens R, Weltens C, Navarria P, Belkacemi Y, Lopez-Guerra J, Livi L, Baumert B, Vieites B, Limon D, Kurman N, Ko K, Yu J, Chiang V, Poortmans P, Zagar T. Discrepancies between biomarkers of primary breast cancer and subsequent brain metastases: an international multicenter study. Breast Cancer Research And Treatment 2017, 167: 479-483. PMID: 28975433, DOI: 10.1007/s10549-017-4526-8.Peer-Reviewed Original ResearchConceptsBreast cancer patientsSubsequent brain metastasesHuman epidermal growth factor receptor 2Brain metastasesCancer patientsEthical research committeeReceptor statusPrimary tumorProgesterone receptorEstrogen receptorEpidermal growth factor receptor 2Triple-negative profileGrowth factor receptor 2Primary breast cancerPrimary breast tumorsInternational multicenter studyFactor receptor 2Multicenter studyAvailable histologyResultsA totalBreast cancerReceptor 2ConclusionsThe majorityPatientsBreast tumors
2010
Analysis of pathologic extent of disease for clinically localized prostate cancer after radical prostatectomy and subsequent use of adjuvant radiation in a national cohort
Schreiber D, Rineer J, Yu J, Olsheski M, Nwokedi E, Schwartz D, Choi K, Rotman M. Analysis of pathologic extent of disease for clinically localized prostate cancer after radical prostatectomy and subsequent use of adjuvant radiation in a national cohort. Cancer 2010, 116: 5757-5766. PMID: 20737571, DOI: 10.1002/cncr.25561.Peer-Reviewed Original ResearchConceptsProstate-specific antigenClinically localized prostate cancerPositive surgical marginsLocalized prostate cancerAdjuvant radiationRadical prostatectomySurgical marginsProstate cancerPathologic extentRate of organ-confined diseaseProstate-specific antigen levelRisk of extraprostatic extensionPatterns of care studyOrgan-confined diseaseNegative surgical marginsEnd Results databaseLogistic regression analysisPopulation-based studyExtraprostatic diseaseExtraprostatic extensionGleason 7Gleason 8Postoperative radiationProstatic adenocarcinomaResults database